Drug news
GSK withdraws from US development of Toctino (alitretinoin) for the treatment of severe hand eczema- Basilea
GSK informed Basilea that it has elected to discontinue its U.S. alitretinoin (Toctino) program. Global rights to Toctino (alitretinoin) were transferred to Stiefel, a GSK company, in July 2012. Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK continues to commercialize Toctino in its current markets.
Comment: Toctino a treatment for severe hand eczema was approved in the UK in 2008.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins